Search Within

David Hyman

  1. "Rachel Grisham"
Formats
  1. Journal Article (16)
  2. Meeting Abstract (12)
  3. Book Section (1)
Groups
  1. Department of Medicine (29)
  2. Early Drug Development Service (29)
  3. GDMT, Medicine (29)
  4. Gynecologic Medicine Service (29)
  5. Gynecology Disease Management Team (29)
  6. Solid Tumor Oncology Division (29)

More Groups

People
  1. Rachel Grisham (29)
  2. Carol Aghajanian (23)
  3. Alexia Iasonos (16)
  4. David Spriggs (15)
  5. Martee Hensley (12)
  6. Roisin O'Cearbhaill (12)

More People

Years
  1. 2020 (2)
  2. 2019 (2)
  3. 2018 (4)
  4. 2017 (2)
  5. 2015 (2)
  6. 2014 (5)

More Years

Publications
  1. Journal of Clinical Oncology (10)
  2. Gynecologic Oncology (4)
  3. Cancer (3)
  4. International Journal of Gynecological Cancer (3)
  5. Clinical Cancer Research (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. American Association for Cancer Research (4)
  3. Elsevier B.V. (4)
  4. Lippincott Williams & Wilkins (4)
  5. Wiley Blackwell (3)
  6. Millennium Medical Publishing, Inc (1)

More Publishers

Results (29)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Single-arm, open-label, phase II study of LY3023414 for the treatment of recurrent or persistent endometrial cancer
    Meeting Abstract

    Rubinstein, M. M.; Hyman, D.; Caird, I.; O'Cearbhaill, R.; Grisham, R.; Tew, W.; Hensley, M.; Sabbatini, P.; Aghajanian, C.; Iasonos, A.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
    Journal Article

    Rubinstein, M. M.; Hyman, D. M.; Caird, I.; Won, H.; Soldan, K.; Seier, K.; Iasonos, A.; Tew, W. P.; O’Cearbhaill, R. E.; Grisham, R. N.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • A phase 2 study of TPIV200/ huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer
    Meeting Abstract

    Zamarin, D.; Yeku, O.; O'Cearbhaill, R. E.; Cadoo, K. A.; Gallagher, J.; Kravetz, S.; McDonnell, A.; Troso-Sandoval, T.; Sabbatini, P.; Lichtman, S.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
    Journal Article

    Boland, J. L.; Zhou, Q.; Martin, M.; Callahan, M. K.; Konner, J.; O'Cearbhaill, R. E.; Friedman, C. F.; Tew, W.; Makker, V.; Grisham, R. N.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer
    Meeting Abstract

    Friedman, C. F.; Donoghue, M.; Vivek, M.; Aghajanian, C.; Abu-Rustum, N.; Cadoo, K. A.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Kyi, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial or ovarian cancer
    Meeting Abstract

    Hyman, D.; Bonafede, M.; O'Cearbhaill, R.; Grisham, R.; Zamarin, D.; Tew, W.; Aghajanian, C.; Cadoo, K.; Friedman, C.; Savage, R. E.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Clinical utility of prospective molecular characterization in advanced endometrial cancer
    Journal Article

    Soumerai, T. E.; Donoghue, M. T. A.; Bandlamudi, C.; Srinivasan, P.; Chang, M. T.; Zamarin, D.; Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Tew, W. P.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • A randomized trial of prophylactic extended carboplatin infusion to reduce hypersensitivity reactions in recurrent ovarian cancer
    Journal Article

    LaVigne, K.; Hyman, D. M.; Zhou, Q. C.; Iasonos, A.; Tew, W. P.; Aghajanian, C.; Makker, V.; Hensley, M. L.; Konner, J.; Grisham, R. N.; more...
    International Journal of Gynecological Cancer (2018)

    Fulltext@MSK | Save
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Somatic mutations in homologous recombination pathway genes in ovarian cancer
    Meeting Abstract

    Aghajanian, C.; DeLair, D.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Makker, V.; O'Cearbhaill, R. E.; Sabbatini, P.; Soumerai, T.; Charen, A. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save